Simufilam (PTI-125) (hydrochloride) is an orally active filamin A (FLNA) activator with low toxicity that can be used in the Alzheimers disease research. Simufilam (hydrochloride) preferentially binds to altered FLNA and restores its native conformation, restores receptor and synaptic activities, and reduces its a7nAChR/TLR4 associations and downstream pathologies [1].